VBI Vaccines Inc. (VBIV) recently announced a pan-coronavirus vaccine candidate, VBI-2901, which comprises of SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins. VBI-2901 is a multivalent vaccine that could produce a broad array of reactive antibodies, which may provide protection from mutated strains of the coronavirus. Now, the company is working with the National Research Council of Canada, "NRC," to bring a candidate to the clinic in Q4 2020. Additionally, the company successfully completed Sci-B-Vac's pivotal Phase III for hepatitis B and is preparing for submissions with the FDA, EMA, and Health Canada. It looks as if VBI has several major catalysts scheduled in the coming quarters that could be transformative events for the company and the stock. However, the stock has already experienced a strong move to the upside following its announcement of its pan-coronavirus vaccine candidate and appears to have found a new trading range around $2.00 per share. I would like to find a spot to add to my speculative position, but I don't want to pay the COVID-19 premium price.
I intend to review the company's recent progress and discuss my opinions about VBI's pan-coronavirus vaccine candidate. Finally, I attempt to find a target price for my next buy and how I plan to manage my position in the second half of 2020.
Pan-Coronavirus Vaccine
VBI Vaccines is one of several vaccine companies in my speculative portfolio that has committed to discovering and developing a COVID-19 vaccine. Admittedly, I didn't expect VBI to become a market leader from its efforts, but I was happy to see the market identify VBI's efforts and potential to produce a cutting-edge vaccine to thwart the pandemic. Not only does VBI's vaccine target COVID-19, but it also includes the spike proteins for severe acute respiratory syndrome, "SARS", and Middle East respiratory syndrome, "MERS". Together, these different strains of coronavirus could create a pan-coronavirus
